NASDAQ:RCKTW Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis $0.04 0.00 (-10.76%) As of 09/12/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Rocket Pharmaceuticals Stock (NASDAQ:RCKTW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0450-Day Range$0.03▼$0.1452-Week Range$0.02▼$0.15Volume19,085 shsAverage Volume23,693 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and often fatal inherited diseases. The company utilizes ex vivo lentiviral vector-based approaches to deliver functional copies of genes into patients’ hematopoietic stem cells. By targeting the underlying genetic defects, Rocket aims to provide potentially curative treatments for disorders that currently rely on lifelong supportive care or conventional interventions. Rocket’s pipeline comprises multiple programs in various stages of development, including treatments for Fanconi anemia, primary immune deficiencies such as PNP deficiency and ADA-SCID, as well as metabolic and cardiac conditions like Danon disease and Barth syndrome. Several of these programs have advanced into clinical trials, reflecting the company’s emphasis on accelerating therapies from preclinical proof-of-concept through regulatory milestones. Founded in 2013 and headquartered in New York, Rocket Pharmaceuticals operates primarily in the United States while collaborating with academic and clinical partners across North America and Europe. The company is led by a management team with extensive experience in gene therapy, hematology and rare disease drug development, and it continues to expand its manufacturing and clinical infrastructure to support future growth.AI Generated. May Contain Errors. Read More Receive RCKTW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKTW Stock News HeadlinesRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | finance.yahoo.comBank of America Upgrades Rocket Pharma Stock (RCKT) After FDA Lifts Clinical Hold on Danon Disease TrialAugust 21, 2025 | msn.comMan who called Tesla in 2018 issues new Tesla alertThe Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.September 14 at 2:00 AM | Brownstone Research (Ad)B of A Securities Upgrades Rocket Pharmaceuticals (RCKT)August 21, 2025 | msn.comRocket Pharma rises as FDA lifts clinical hold on gene therapy trialAugust 20, 2025 | msn.comRocket Pharmaceuticals stock soars after FDA lifts clinical holdAugust 20, 2025 | investing.comRocket Pharmaceuticals upgraded to Buy from Neutral at BofAAugust 20, 2025 | msn.comRocket Pharma's shares soar after US FDA lets gene therapy trial resumeAugust 20, 2025 | msn.comSee More Headlines RCKTW Stock Analysis - Frequently Asked Questions How have RCKTW shares performed this year? Rocket Pharmaceuticals' stock was trading at $0.0343 on January 1st, 2025. Since then, RCKTW shares have increased by 8.5% and is now trading at $0.0372. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKTW CIK1281895 Webwww.rocketpharma.com Phone16464409100FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:RCKTW) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.